Eckert & Ziegler Reports Robust 2025 Financial Performance and Optimistic 2026 Forecast

In 2025, Eckert & Ziegler SE achieved record sales of €312 million, marking a 5% increase from the previous year. The company's adjusted EBIT rose significantly by 18% to €77.7 million, while net income increased by 46% to €48.8 million, translating to earnings per share of €0.78. A substantial contribution came from the Medical segment, where sales grew by 15%. Conversely, the Isotope Products segment saw a decline due to a shift towards lower-margin products and cyberattack-induced delays.

For 2026, the company forecasts sales of approximately €320 million and an adjusted EBIT of €80 million. This optimistic outlook anticipates a 9% sales growth and a 21% earnings increase, even as the company navigates currency fluctuations and advances its licensing business. The Executive Board proposes a dividend of €0.22 per share, reflecting confidence in the company's continued growth trajectory.